JLPC(SH:600513) Ge Long Hui A P P·2026-01-23 10:26Core Viewpoint - The company, Lianhuan Pharmaceutical, is expected to report a significant decline in net profit for the year 2025, transitioning from profit to loss due to various adverse factors [1]. Financial Performance - The estimated net profit attributable to shareholders for 2025 is projected to be between -99 million RMB and -83 million RMB, indicating a shift from profit to loss [1]. - The estimated net profit excluding non-recurring items is expected to range from -39 million RMB to -32.5 million RMB, representing a decrease of 82.368 million RMB to 88.868 million RMB compared to the previous year [1]. Operational Factors - The company's overall operations remain stable; however, it faces pressure on gross margins for its main products due to national drug procurement policies, adjustments in medical insurance payment policies, and intensified competition in international markets [1]. - The company has incurred non-recurring expenses due to administrative penalties, which have contributed to the decline in net profit [1]. - Increased investment in research and development for innovative drugs has led to a rise in R&D expenses and related costs, further impacting profitability [1].